// App-Quantinova.ai

123 : Salvage chemotherapy with cisplatin, ifosfamide, and paclitaxel in metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Gunhild Von Amsberg

Principal Investigators

  • Mirjam Zilles

  • Philipp Gild

  • Winfried Alsdorf

  • Lukas Boeckelmann

  • Claudia Langebrake

  • Su Jung Oh-Hohenhorst

  • Derya Tilki

  • Markus Graefen

  • Sergey Dyshlovoy

  • Carsten Bokemeyer

Medical Centers

  • Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany

  • Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany

  • Department of Gynecology Universtiy College Hospital Hamburg Eppendorf (UKE), Hamburg, Germany

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany

  • Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Medical University Hamburg-Eppendorf, Martini-Klinik, Hamburg, Germany

  • Martini-Clinic, Hamburg, Germany

  • School of Natural Sciences, Far Eastern Federal University, Vladivostok, Russian Federation

Locations

  • Germany

  • Russia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

  • Prostate cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Ifosfamide

  • Paclitaxel

  • Docetaxel

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved